Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ALT

ALT - Altimmune Inc Stock Price, Fair Value and News

6.38USD+0.44 (+7.41%)Delayed

Market Summary

ALT
USD6.38+0.44
Delayed
7.41%

ALT Stock Price

View Fullscreen

ALT RSI Chart

ALT Valuation

Market Cap

452.4M

Price/Earnings (Trailing)

-4.88

Price/Sales (Trailing)

1.1K

EV/EBITDA

-3.84

Price/Free Cashflow

-6.21

ALT Price/Sales (Trailing)

ALT Profitability

EBT Margin

-22930.75%

Return on Equity

-53.64%

Return on Assets

-49.25%

Free Cashflow Yield

-16.1%

ALT Fundamentals

ALT Revenue

Revenue (TTM)

426.0K

Rev. Growth (Yr)

18.0K%

Rev. Growth (Qtr)

-89.78%

ALT Earnings

Earnings (TTM)

-92.8M

Earnings Growth (Yr)

-21.52%

Earnings Growth (Qtr)

22.9%

Breaking Down ALT Revenue

Last 7 days

4.4%

Last 30 days

-19.1%

Last 90 days

-29.7%

Trailing 12 Months

53.4%

How does ALT drawdown profile look like?

ALT Financial Health

Current Ratio

16.55

Debt/Equity

0

Debt/Cashflow

-123.28

ALT Investor Care

Shares Dilution (1Y)

43.84%

Diluted EPS (TTM)

-1.61

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
2023911.6K37.0K391.0K426.0K
20223.5M2.7M1.8M0
20216.8M6.2M3.4M4.4M
20205.1M4.2M6.4M8.2M
201910.6M9.8M7.8M5.8M
201813.1M12.5M10.6M10.3M
20173.1M5.4M9.0M10.7M
20164.6M4.2M3.9M3.8M
201513.5M11.0M11.2M10.6M
201415.2M14.5M12.0M10.2M
201325.5M23.5M20.3M17.9M
201224.1M24.0M25.4M25.2M
201121.8M22.6M23.4M24.3M
201000021.0M

Tracking the Latest Insider Buys and Sells of Altimmune Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 02, 2024
roberts m scot
acquired
-
-
7,775
chief scientific officer
Feb 02, 2024
garg vipin k
acquired
-
-
18,950
president and ceo
Feb 02, 2024
garg vipin k
sold (taxes)
-78,064
9.32
-8,376
president and ceo
Feb 02, 2024
roberts m scot
sold (taxes)
-21,715
9.32
-2,330
chief scientific officer
Feb 02, 2024
harris matthew scott
sold (taxes)
-21,734
9.32
-2,332
chief medical officer
Feb 02, 2024
harris matthew scott
acquired
-
-
7,775
chief medical officer
Feb 01, 2024
garg vipin k
acquired
-
-
16,545
president and ceo
Feb 01, 2024
roberts m scot
sold (taxes)
-17,793
9.88
-1,801
chief scientific officer
Feb 01, 2024
roberts m scot
acquired
-
-
6,166
chief scientific officer
Feb 01, 2024
garg vipin k
sold (taxes)
-72,252
9.88
-7,313
president and ceo

1–10 of 50

Which funds bought or sold ALT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
sold off
-100
-534,000
-
-%
May 24, 2024
Cetera Investment Advisers
new
-
665,120
665,120
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
added
1,282
4,402,100
4,784,600
0.02%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-82.5
-5,495,940
1,034,050
-%
May 16, 2024
COMERICA BANK
new
-
7,513
7,513
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
517
449,118
546,971
-%
May 16, 2024
Tidal Investments LLC
new
-
140,759
140,759
-%
May 16, 2024
Arete Wealth Advisors, LLC
sold off
-100
-137,250
-
-%
May 15, 2024
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
unchanged
-
-107
1,018
-%
May 15, 2024
AMUNDI
sold off
-100
-409,872
-
-%

1–10 of 42

Are Funds Buying or Selling ALT?

Are funds buying ALT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALT
No. of Funds

Unveiling Altimmune Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 10, 2024
state street corp
12.20%
8,649,270
SC 13G/A
Mar 05, 2024
millennium management llc
5.4%
2,911,937
SC 13G
Feb 14, 2024
ameriprise financial inc
7.79%
4,183,682
SC 13G
Feb 14, 2024
nuveen asset management, llc
0.01%
6,679
SC 13G/A
Feb 14, 2024
teachers advisors, llc
0.01%
6,679
SC 13G/A
Feb 14, 2024
tiaa cref investment management llc
0.01%
6,679
SC 13G/A
Feb 14, 2024
avidity partners management lp
0.0%
0
SC 13G/A
Feb 14, 2024
tang capital partners lp
5.1%
2,750,000
SC 13G/A
Feb 13, 2024
vanguard group inc
6.65%
3,571,972
SC 13G/A
Feb 12, 2024
janus henderson group plc
0.0%
273
SC 13G/A

Recent SEC filings of Altimmune Inc

View All Filings
Date Filed Form Type Document
May 09, 2024
8-K
Current Report
May 09, 2024
10-Q
Quarterly Report
Apr 10, 2024
SC 13G/A
Major Ownership Report
Mar 27, 2024
S-8
Employee Benefits Plan
Mar 27, 2024
8-K
Current Report
Mar 27, 2024
10-K
Annual Report

Peers (Alternatives to Altimmune Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
-18.41% 10.61%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.9B
2.0B
9.73% -16.82%
-63.08
10.46
75.20% 68.82%
15.9B
2.5B
9.61% -12.35%
77.45
6.44
13.74% 186.89%
14.2B
3.8B
8.63% 2.12%
19.04
3.77
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.36
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.81
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.26
14.48
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.7
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.94
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
28.28
4.48
60.38% -34.49%
453.7M
881.7K
-5.58% 440.76%
-13.44
481.06
-77.61% 33.36%
209.4M
4.2M
-28.18% 49.63%
-1.68
50.33
-66.30% 48.24%
18.2M
2.1M
-6.22% 224.62%
-0.79
7.61
-13.45% 69.54%

Altimmune Inc News

Latest updates
Defense World32 hours ago
InvestorPlace3 months ago

Altimmune Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-100.0%-37,000362,0006,00021,0002,0008,0001,642,5003,277,000158,000137,000838,0002,312,7062,937,991721,6362,212,694575,802643,9781,626,0292,955,5922,588,655
Operating Expenses-20.4%26,799,00033,660,00022,902,00018,013,00021,780,00024,754,00020,403,00019,531,00027,262,00033,362,00025,001,00015,699,00013,062,50121,262,21319,139,6069,519,4484,887,91211,917,3585,176,9135,284,15329,934,635
  S&GA Expenses22.6%5,312,0004,332,0004,514,0004,760,0004,531,0004,492,0004,410,0004,427,0003,777,0004,156,0003,659,0003,821,0004,111,9294,220,2382,545,3562,331,9172,014,8232,187,6612,231,8172,066,4822,419,951
  R&D Expenses27.1%21,487,00016,909,00018,388,00013,253,00017,249,00020,262,00015,993,00015,104,00020,185,00029,206,00013,272,00011,878,0008,950,57217,041,97516,594,2507,187,5312,873,0898,729,6972,945,0963,217,6713,064,673
EBITDA Margin0.0%-228-228-20.64-23.45-23.31-23.96-21.86-21.87-21.89-24.15-10.96-9.07---------
Interest Expenses-50.0%1,0002,00029,0002,0002,00064,00065,00062,000-62,00033,00022,00012,0001,9532,2753,3081,885-756748740127,353
Income Taxes-------197,000-------110,346-482,017-1,578,782-3,245,879--58,500---2,831,670
Earnings Before Taxes100.0%--31,641,000-20,671,000---23,713,000---23,889,092-33,510,000-24,826,707-14,864,108-10,732,123-18,252,152-18,345,698-7,131,528-4,096,625-10,997,812-3,386,888-2,097,306-27,339,293
EBT Margin0%-229-229-20.39-23.30-23.30-24.02-22.02-22.02-22.02-24.36-11.03-9.13---------
Net Income22.9%-24,394,000-31,641,000-20,671,000-16,061,000-20,074,000-23,516,000-20,107,000-19,430,000-23,889,000-33,510,000-24,827,000-14,864,000-10,621,777-17,770,135-16,766,916-3,885,649-4,096,625-10,939,312-3,386,888-2,097,306-24,507,623
Net Income Margin-4.9%-217-207-17.79-18.44-19.36-19.71-21.98-23.05-22.02-24.33-10.94-8.81---------
Free Cashflow1.1%-16,357,000-16,533,000-20,487,000-19,379,000-19,458,000-15,110,000-16,723,000-13,535,000-22,114,000-17,845,000-26,618,000-23,778,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-10.6%18821116718318720722521020621923725726424523310354.0054.0056.0062.0065.00
  Current Assets-10.5%18821015317017319321119619120421823924523021888.0040.0039.0042.0046.0049.00
    Cash Equivalents-41.5%79.0013587.0010210511112713618019017517415011614465.0011.009.0011.0042.0045.00
  Net PPE-16.4%1.001.001.001.001.001.001.001.001.001.005.005.005.001.001.001.001.001.001.001.001.00
Liabilities-6.8%15.0017.0016.0016.0019.0022.0020.0015.0021.0020.0028.0016.0018.0019.0033.0023.0012.009.007.006.006.00
  Current Liabilities-6.7%11.0012.0012.0011.0015.0017.0016.0014.0019.0018.0019.009.0010.0012.006.005.006.004.002.003.004.00
Shareholder's Equity-10.9%17319415016816818520519518519920924124622620080.0042.0046.0049.0056.0059.00
  Retained Earnings-5.2%-490-466-434-414-397-377-356-332-312-293-269-235-210-186-175-158-141-137-133-122-118
  Additional Paid-In Capital0.5%669665590587571568567532503497484482462417381243188188188184183
Shares Outstanding0.3%71.0071.0053.0053.0050.0049.0049.0044.0044.0041.0041.0040.00---------
Float----184---538---387---281---29.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations1.1%-16,357-16,533-20,487-19,383-19,407-17,306-15,050-16,704-13,526-21,967-17,775-18,927-19,569-13,282-9,504-7,170-4,347-2,002-2,426-3,060-2,112
  Share Based Compensation47.8%3,6502,4692,7102,7862,6751,8922,1282,0482,0331,3191,4971,4851,2187101,320331215279288290408
Cashflow From Investing-396.6%-39,521-7,9594,4023,98713,302981-25,403-48,968-9.0024,86918,41125,07819,165-36,999-47,8886,0986,563-52.68-28,216-12.85-4.25
Cashflow From Financing-100.4%-26172,75458813,065-302-43.0032,06021,5833,18112,53512518,01934,41922,704136,14654,53997.0045.00-55.79-15612,699
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ALT Income Statement

2024-03-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS  
Revenues$ 5$ 21
Operating expenses:  
Research and development21,48717,249
General and administrative5,3124,531
Total operating expenses26,79921,780
Loss from operations(26,794)(21,759)
Other income (expense):  
Interest expense(1)(2)
Interest income2,4131,668
Other income (expense), net(12)19
Total other income (expense), net2,4001,685
Net loss(24,394)(20,074)
Other comprehensive income - unrealized (loss) gain on short-term investments(157)126
Comprehensive loss$ (24,551)$ (19,948)
Net loss per share, basic$ (0.34)$ (0.40)
Net loss per share, diluted$ (0.34)$ (0.40)
Weighted-average common shares outstanding, basic70,801,71350,125,685
Weighted-average common shares outstanding, diluted70,801,71350,125,685

ALT Balance Sheet

2024-03-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 78,978$ 135,117
Restricted cash4141
Total cash, cash equivalents and restricted cash79,019135,158
Short-term investments103,04662,698
Accounts and other receivables3071,111
Income tax and R&D incentive receivables2,2723,742
Prepaid expenses and other current assets2,8716,917
Total current assets187,515209,626
Property and equipment, net544651
Other assets299363
Total assets188,358210,640
Current liabilities:  
Accounts payable3,7602,070
Accrued expenses and other current liabilities7,57310,073
Total current liabilities11,33312,143
Noncurrent liabilities4,0884,398
Total liabilities15,42116,541
Commitments and contingencies (Note 10)
Stockholders' equity:  
Common stock, $0.0001 par value; 200,000,000 shares authorized; 70,899,134 and 70,677,400 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively77
Additional paid-in capital668,816665,427
Accumulated deficit(490,725)(466,331)
Accumulated other comprehensive loss, net(5,161)(5,004)
Total stockholders' equity172,937194,099
Total liabilities and stockholders' equity$ 188,358$ 210,640
ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
 CEO
 WEBSITEhttps://altimmune.com
 INDUSTRYBiotechnology
 EMPLOYEES52

Altimmune Inc Frequently Asked Questions


What is the ticker symbol for Altimmune Inc? What does ALT stand for in stocks?

ALT is the stock ticker symbol of Altimmune Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Altimmune Inc (ALT)?

As of Fri Jun 21 2024, market cap of Altimmune Inc is 452.36 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALT stock?

You can check ALT's fair value in chart for subscribers.

What is the fair value of ALT stock?

You can check ALT's fair value in chart for subscribers. The fair value of Altimmune Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Altimmune Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Altimmune Inc a good stock to buy?

The fair value guage provides a quick view whether ALT is over valued or under valued. Whether Altimmune Inc is cheap or expensive depends on the assumptions which impact Altimmune Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALT.

What is Altimmune Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, ALT's PE ratio (Price to Earnings) is -4.88 and Price to Sales (PS) ratio is 1.06 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Altimmune Inc's stock?

In the past 10 years, Altimmune Inc has provided -0.187 (multiply by 100 for percentage) rate of return.